drugset / Trial / NCT05943314
Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia
Withdrawn
Guangzhou Bio-gene Technology Co., Ltd
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, open, intravenous drug administration of the safety and efficacy of clinical study.
Timeline
- Start
- 2023-07-12
- Primary completion
- 2023-08-28
- Completion
- 2023-08-28
Outcome
Outcome not reported
Stopped (Business): “The clinical trial was terminated due to a change in sponsor strategy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | 2.5e+06 cells/kg | Intravenous |